Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Newer antistaphylococcal agents.

John S Bradley1

  • 1Division of Infectious Diseases, Children's Hospital San Diego, San Diego, California 92123, USA. jbradley@chsd.org

Current Opinion in Pediatrics
|January 22, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase 2/3, Open-label, Randomized, Active-controlled Clinical Trial Evaluating the Safety and Efficacy of Imipenem/Cilastatin/Relebactam in Pediatric Patients From Birth to Less Than 18 Years With Gram-negative Bacterial Infections.

The Pediatric infectious disease journal·2026
Same author

Correlation Between Renal Biomarkers, Glomerular Filtration Rate, and Meropenem Clearance in Pediatric Septic Shock.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2026
Same author

Pneumococcal Pneumonia in Hospitalized Children: 2017-2023.

Pediatrics·2026
Same author

Successful Bacteriophage Treatment of a Recalcitrant Intra-Abdominal Infection Caused by Multidrug-Resistant Pseudomonas aeruginosa in a 2-Year-Old Child.

The Journal of pediatrics·2026
Same author

Evaluation of Aminoglycoside Dosing Regimens Adjusted for Renal Function and In Vitro Susceptibility Test Interpretive Criteria for Enterobacterales and <i>Pseudomonas aeruginosa</i>: Brief Summary.

Open forum infectious diseases·2025
Same author

Evaluation of Aminoglycoside Dosing Regimens Adjusted for Renal Function and In Vitro Susceptibility Test Interpretive Criteria for Enterobacterales and <i>Pseudomonas aeruginosa</i>.

Open forum infectious diseases·2025

Antibiotic resistance in staphylococci is rising, impacting pediatric treatments. Assessing local resistance patterns is crucial for effective empiric and definitive antibiotic therapy decisions in children.

Area of Science:

  • Pediatric Infectious Diseases
  • Antimicrobial Resistance
  • Staphylococcal Infections

Background:

  • Increasing antibiotic resistance in staphylococci, including methicillin-resistant Staphylococcus aureus (MRSA), challenges traditional pediatric treatments with first-generation cephalosporins, penicillins, and macrolides.
  • Local resistance trends are critical for guiding empiric antibiotic therapy decisions in pediatric staphylococcal infections.
  • Assessing pathogen-specific resistance patterns allows for informed selection of alternative antibiotic agents for definitive therapy.

Purpose of the Study:

  • To review the evolving landscape of antibiotic resistance in staphylococci affecting children.
  • To highlight the importance of understanding local resistance patterns for effective treatment strategies.
  • To discuss current and emerging therapeutic options for staphylococcal infections in pediatric populations.

Related Experiment Videos

Main Methods:

  • Review of current literature on antibiotic resistance trends in staphylococci.
  • Analysis of therapeutic options for community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) in children.
  • Evaluation of newly approved and investigational agents for staphylococcal infections.

Main Results:

  • Treatment of MRSA and macrolide-resistant Staphylococcus aureus in children may involve vancomycin, linezolid, or clindamycin (if susceptible).
  • Daptomycin is approved for adults, with second-generation glycopeptides (dalbavancin, oritavancin) in adult clinical trials.
  • New cephalosporins active against MRSA are in preclinical development.

Conclusions:

  • The rise of CA-MRSA necessitates a revised approach to treating staphylococcal infections in pediatric care.
  • Newer agents like linezolid are approved for children, while adult-approved medications are under investigation for pediatric use.
  • Older, less costly antibiotic agents may still offer effective treatment options for staphylococcal infections, though data from prospective studies are limited.